Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Net Income (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Net Income for 17 consecutive years, with -$1.9 million as the latest value for Q1 2026.

  • Quarterly Net Income fell 167.89% to -$1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.5 million through Jan 2026, up 1.51% year-over-year, with the annual reading at -$3.0 million for FY2025, 42.16% up from the prior year.
  • Net Income for Q1 2026 was -$1.9 million at PharmaCyte Biotech, down from -$1.2 million in the prior quarter.
  • The five-year high for Net Income was -$180346.0 in Q2 2023, with the low at -$2.4 million in Q2 2024.
  • Average Net Income over 5 years is -$1.1 million, with a median of -$917094.0 recorded in 2023.
  • The sharpest move saw Net Income skyrocketed 87.31% in 2023, then tumbled 1241.38% in 2024.
  • Over 5 years, Net Income stood at -$1.9 million in 2022, then soared by 72.58% to -$515339.0 in 2023, then crashed by 40.39% to -$723498.0 in 2024, then crashed by 61.67% to -$1.2 million in 2025, then crashed by 61.37% to -$1.9 million in 2026.
  • According to Business Quant data, Net Income over the past three periods came in at -$1.9 million, -$1.2 million, and -$630512.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.